Lexaria Launches GLP-1 Animal Study with 8–11 Arms to Secure SNAC Alternative IP
Lexaria has contracted a CRO for its GLP-1-A26-1 animal study using DHT-semaglutide and DHT-CBD formulations, aiming to begin dosing within 60 days and assess pharmacokinetics and brain biodistribution in 8–11 study arms. The fully funded study seeks formulations superior to SNAC to secure patents and bolster DehydraTECH IP.
1. CRO Contract and Timeline
Lexaria has signed contracts with a CRO to conduct its GLP-1-A26-1 animal study evaluating DHT-semaglutide and DHT-CBD compositions. Materials sourcing is underway and study design is being finalized, with dosing set to commence within approximately 60 days.
2. Study Design and Measures
The study will utilize Sprague-Dawley rats across eight to eleven arms to assess pharmacokinetics and brain biodistribution of novel formulations over an 8–24-hour post-dosing period. Blood and brain samples will be collected at multiple timepoints to quantify absorption and distribution metrics.
3. SNAC Alternative Formulations
One objective is to develop formulations that outperform SNAC, the salcaprozate sodium excipient used in leading oral GLP-1 drugs. Lexaria aims to demonstrate superior performance to support new patent filings for its DehydraTECH platform.
4. Funding and Strategic Implications
The study is fully funded from existing corporate resources. Securing new IP could position Lexaria as a key provider of enhanced oral GLP-1 delivery technology and strengthen its global patent portfolio.